• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21936 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychological Treatment for Postpartum Depression]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Psychological aspects, women's views, and expectations regarding ultrasound during pregnancy]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psycho- and sociotherapeutic interventions: Adults - Evidence report on the S3 guideline "Cannabis-related disorders"]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psycho- and sociotherapeutic interventions: Adolescents - Evidence report on the S3 guideline "Cannabis-related disorders"]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [PSMA PET/CT staging in patients with prostate cancer biochemical recurrence]
2009     Committee for New Health Technology Assessment (CNHTA) [PRSS1 gene, Mutation[Sequencing]]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Proxy HRQL value measurement in Alzheimer's dementia]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Proton therapy]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Proton therapy in cancer treatment. Update]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Protein-sparing modified fast diet: efficacity, safety and clinical use - literature review]
2012     Andalusian Health Technology Assessment Area (AETSA) [Protease inhibitors (Boceprevir and telaprevir) in the treatment of chronic HCV infection: relative efficacy, safety and efficiency]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Prosthesis replacement in ankle osteoarthritis]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Prostate rectum spacing in prostate radiation therapy]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Prostate cancer; does the use of fusion biopsy lead to better treatment results compared to the use of conventional diagnostic procedures?]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Prostate cancer screening with the PSA test]
2009     Committee for New Health Technology Assessment (CNHTA) [PROS1 exon deletion/duplication test[MLPA]]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Propranolol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Proposed health survey of the Basque Country for institutionalised population in nursing homes (ESCAV-IR). CAPV 2010]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Proposals and approaches for reporting study results using "number needed to treat" (NNT) as the effect measure]
2020     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Proposal for the organization of bariatric medicine for the territories of the integrated university health and social services network of Laval University]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Proposal for a programme for the early detection of infant deafness in the Basque Autonomous Community]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Prompt therapy in patients with speech disorders]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Promoting mental well-being in children and adolescents]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Promising measures to reduce the use of avoidable obstetrical interventions with low-risk women]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Promising measures to reduce the use of a avoidable obstetrical interventions with low-risk women]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Prolotherapy in chronic musculoskeletal disorders]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Programs for preventing suicide and suicide attempt in children]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events]
2014     Andalusian Health Technology Assessment Area (AETSA) [Prognostic genomic tests in early breast cancer: MammaPrint® and Oncotype DX®]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Profile of individuals insured by the public prescription drug insurance plan who have received treatment for hepatitis C (HCV)]
2009     Gesundheit Osterreich GmbH (GOeG) [Professional dental prophylaxis]
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Process and evaluation of digital health applications in the context of "symptom-checkers"]
2012     Haute Autorite de sante (HAS) [Procedures for symmetrisation of the contralateral breast following breast cancer surgery]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Procedures and criteria for the regulation of innovative non-medicinal technologies into the benefit catalogue of solidly financed health care insurances]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Procedures and criteria for the regulation of innovative non-medicinal technologies into the benefit catalogue of solidly financed health care insurances]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Procedure for lung volume reduction in severe lung emphysema]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Procalcitonin-guided antibiotic therapy for acute infections]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Procalcitonin assay for optimizing the use of antibiotics in the treatment of infections]
2008     Committee for New Health Technology Assessment (CNHTA) [Procalcitonin (PCT) quantitation]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Probiotics in the prevention of clostridium difficile-associated colitis and antibiotic associated diarrhea in adult in-patients]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Pro-BNP Peptide in the diagnosis and prognosis of heart failure]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Pro-BNP peptide in the diagnosis and prognosis of heart failure]
2010     Committee for New Health Technology Assessment (CNHTA) [Pro gastrin-releasing peptide test]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Priorization for patients on waiting lists: development of a generic system]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Priority-setting of patients on waiting list for spine or spinal fusion elective surgery]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Priority setting of clinical preventive services for benefits extension]
2015     National Evidence-based Healthcare Collaborating Agency (NECA) [Priority setting for health technology assessment(HTA) research in Korea]
2011     Andalusian Health Technology Assessment Area (AETSA) [Prioritization of patient decision aids]
2017     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Primary section - surgical techniques and reimbursement]
2003     Norwegian Knowledge Centre for the Health Services (NOKC) [Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Primary prevention and health promotion in men]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Primary maximal necrosectomy versus a minimally invasive step up approach in patients with necrotising pancreatitis; PANTER, a randomised controlled trial. Dutch Acute Pancreatitis Study Group]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Primary G-CSF prophylaxis during the first two cycles only or throughout all chemotherapy cycles in breast cancer patients at risk of febrile neutropenia]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Primary care interventions provided to families where children have been subjected to abuse and neglect]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Primary bariatric endoscopic techniques in adults with or without type 2 diabetes mellitus. Efficacy, effectiveness, and safety]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Price and cost development of orphan drugs]
2009     Committee for New Health Technology Assessment (CNHTA) [PRF1, UNC13D, STX11 gene, mutation[Sequencing]]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Preventive outpatient treatment in affective disorders. Results from a health technology assessment]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Preventive health screenings and health consultations in primary care]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Preventive effects of integrated multidisciplinary care ("ketenzorg") on disabled persons within homes for the elderly, a naturalistic controlled clinical trial]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Prevention of Type 2 Diabetes Mellitus in Primary Health Care through healthy lifestyles: care and recommended clinical interventions]
2013     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Prevention of nephropathy by iodinated contrast media during a radiological intervention]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Prevention of infection after knee arthroplasty]
2013     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Prevention of fetal alcohol syndrome]
2012     Norwegian Knowledge Centre for the Health Services (NOKC) [Prevention of allergy among children]
2011     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Prevention of alcohol misuse among children, youths and young adults]
2011     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Prevention of alcohol misuse among children, youths and young adults]
2009     Health Council of the Netherlands Gezondheidsraad (GR) [Prevention in the elderly: Focus on functioning in daily life]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Preventing preterm birth in women with a previous preterm birth: identification of obstacles to change]
2009     Committee for New Health Technology Assessment (CNHTA) [Pressure wire]
2013     National Evidence-based Healthcare Collaborating Agency (NECA) [Prescription patterns and safety of benzodiazepines in Korea]
1997     Basque Office for Health Technology Assessment (OSTEBA) [Prescription and management of the hormonal oral contraception (Consensus conference)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Preoperative virtual planning assisted surgery]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Preoperative risk factors: evidence report for the S3 guideline on treatment of inflammatory diseases of the palatine tonsils/tonsillitis]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Preoperative biliary drainage in patients with obstructive jaundice]
2007     Basque Office for Health Technology Assessment (OSTEBA) [Prenatal screening of down syndrome]
2010     Health Council of the Netherlands Gezondheidsraad (GR) [Prenatal screening for trisomy 13 and 18]
2021     Canary Health Service [Prenatal screening for toxoplasmosis]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Prenatal screening for Down syndrome through fetal DNA sequencing from maternal blood]
2011     Andalusian Health Technology Assessment Area (AETSA) [Prenatal screening for aneuploidy using free fetal DNA in maternal blood. Systematic review of the literature.]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Prenatal diagnosis]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Prenatal diagnosis: MLPA or karyotyping]
2016     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Prenatal diagnosis through Next Generation Sequencing (NGS)]
2016     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Prenatal diagnosis through Chromosomal Microarray Analysis (CMA)]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Prenatal cell-free DNA in maternal blood screening to assess chromosomal disorders in single pregnancy]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Preimplantational genetic diagnosis (pgt-a) in assisted reproduction technologies]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Preimplantational diagnosis of fragile chromosome X carriers and other hereditary disorders in artificial fertilisation techniques]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Preimplantation genetic screening (PGS) in patients undergoing high-complexity reproduction technologies]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Preimplantation genetic diagnosis - a health technology assessment]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Pregnancy-induced hypertension and pre-eclampsia after 36 weeks: induction of labour versus expectant monitoring. A comparison of maternal and neonatal outcome, maternal quality of life and costs?]
2009     Health Council of the Netherlands Gezondheidsraad (GR) [Pregnancy immunisation by red blood cells]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Predicting efficient implementation and costs; ultrasound screening for developmental dysplasia of the hip]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Precice® motorized intramedullary nail system for limb-length discrepancy]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Precice® intramedullary nail system, with external remote controller, for limb length discrepancy]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Pre-hospital ECMO for refractory cardiac arrest]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Prasugrel in the treatment of acute coronary syndrome]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pralsetinib (RET fusion-positive NSCLC) - Benefit assessment according to §35a Social Code Book V]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Power Doppler for inflammatory arthropathies]